Loic Vincent

Loic Vincent

Company: Affini-T Therapeutics

Job title: Chief Scientific Officer


Pre-Clinical Development of Safe & Effective T Cell Receptor-Engineered CD4+ & CD8+ T Cell Therapies Specific for Mutant KRAS 10:00 am

Advantages of TCR-engineered CD4+ and CD8+ T cell therapies to induce deep and durable anti-tumor responses against KRas mutant tumors Preclinical data of TCR-engineered T cell therapies targeting KRas mutant tumors Synthetic biology strategy for boosting TCR-engineered T cell trafficking and persistence in the hostile TME of KRas mutant tumors to ensure durable responsesRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.